XML 38 R31.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information (Tables)
9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Schedule of Reconciliation of Significant Segment Expenses

A reconciliation of the Company’s significant segment expenses to net loss is as follows:

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

(in thousands)

 

2025

 

 

2024

 

 

2025

 

 

2024

 

External R&D program expenses:

 

 

 

 

 

 

 

 

 

 

 

 

ARTISTRY-6

 

$

(4,802

)

 

$

3,075

 

 

$

3,898

 

 

$

6,907

 

ARTISTRY-7

 

 

(71

)

 

 

4,801

 

 

 

4,778

 

 

 

15,591

 

Early discovery programs

 

 

11

 

 

 

700

 

 

 

5,341

 

 

 

2,142

 

Other external R&D program expenses(1)

 

 

77

 

 

 

8,737

 

 

 

16,217

 

 

 

25,198

 

Total external R&D program expenses

 

 

(4,785

)

 

 

17,313

 

 

 

30,234

 

 

 

49,838

 

Internal R&D expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Employee-related

 

 

493

 

 

 

7,635

 

 

 

12,386

 

 

 

24,143

 

Other internal R&D expenses(2)

 

 

4

 

 

 

2,637

 

 

 

3,794

 

 

 

8,016

 

Total internal R&D expenses

 

 

497

 

 

 

10,272

 

 

 

16,180

 

 

 

32,159

 

Total R&D expenses

 

 

(4,288

)

 

 

27,585

 

 

 

46,414

 

 

 

81,997

 

G&A expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Employee-related

 

 

980

 

 

 

3,443

 

 

 

6,823

 

 

 

11,170

 

Other G&A expenses(3)

 

 

7,274

 

 

 

3,070

 

 

 

16,469

 

 

 

9,241

 

Total G&A expenses

 

 

8,254

 

 

 

6,513

 

 

 

23,292

 

 

 

20,411

 

Restructuring expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Employee-related

 

 

 

 

 

 

 

 

9,457

 

 

 

 

Other restructuring expenses(4)

 

 

 

 

 

 

 

 

8,029

 

 

 

 

Total restructuring expenses:

 

 

 

 

 

 

 

 

17,486

 

 

 

 

Other segment (income) expense(5)

 

 

(260

)

 

 

(2,339

)

 

 

(2,367

)

 

 

(8,168

)

Segment net loss

 

$

3,706

 

 

$

31,759

 

 

$

84,825

 

 

$

94,240

 

(1) Other external R&D program expenses included in segment net loss include expenses related to other clinical trials and general external program expenses.

(2) Other internal R&D expenses included in segment net loss include expenses related to occupancy and depreciation.

(3) Other G&A expenses included in segment net loss include expenses related to professional fees, information technology, depreciation, and other general G&A expenses.

(4) Other restructuring expenses include contract termination costs, impairment and asset write-offs incurred in connection with our reduction-in-force and the termination of certain development programs.

(5) Other non-operating (income) expense included in segment net loss includes interest income, tax expense, and other non-operating income and expense.